ABSTRACT
INTRODUCTION
Galectin-3 is one of the best-studied galectins. Like all members of the lectin family, Galectin-3 has a high affinity for binding β-galactoside and shares a conserved carbohydrate recognition domain (CRD) (1) . As a chimeric protein with unique structure, Galectin-3 contains three distinct structural regions: 1) an NH 2 terminus containing a serine phosphorylation site that is important for regulation of intracellular signalling; 2) a repetitive, prolinerich, collagen-α-like sequence cleavable by matrix metalloproteases (e.g., MMP-2 and MMP-9); and 3) a globular COOH-terminus containing a carbohydrate recognition domain and the anti-death motif NWGR. Upon binding to multivalent carbohydrates, Galectin-3 can oligomerize through its NH 2 -terminus or form a pentameric lattice structure on the cell surface ( Figure 1A ) (1) . Тhus, it is involved in modulation of intracellular signalling pathways.
As a small molecular weight protein (approximately 30 kDa), Galectin-3 has multiple cellular localizations in many types of cells, in particular, epithelial and immune cells. In general, Galectin-3 serves as a regulator of fundamental biological processes, such as cell proliferation and differentiation, adhesion, migration, survival, apoptosis and immune responses (2) . Intracellularly, Galectin-3 occurs mainly in the cytosol, but is also found in the nucleus (3) and mitochondria (4, 5) . Finally, it can be transported to the cell surface or secreted to the outside of cells. Galectin-3 interacts and co-operates with numerous intra-and extracellular ligands, thus participating in processes that are essential for basic cellular functions. For example, nuclear Galectin-3 acts as an mRNA splicing promoter and modulator of cell growth and proliferation (1, 6, 7) . However, depending on its cellular localization, Galectin-3 may display dual effects, acting as both a negative and positive regulator of apoptosis. Cytoplasmic Galectin-3 functions as an apoptosis inhibitor by maintaining the membrane integrity of mitochondria. In contrast to cytoplasmic Galectin- 3 , it has been demonstrated that nuclear and extracellular Galectin-3 promote apoptosis (8) (9) (10) . After bind- ing to cell surface molecules (e.g., CD29, CD7, CD95 and the T-cell receptor), extracellular Galectin-3 may mediate apoptosis, induced by cytochrome-c release and caspase-3 activation (11) (12) (13) .
Many reports suggest that extracellular Galectin-3 can act as a modulator of cellular adhesion. The multivalent characteristic of Galectin-3 enables it to act as a bridge between adjacent cells, as well as between cells and a plethora of extracellular matrix components (1, 14, 15) , by simultaneously binding to carbohydrates on two adhesion ligands ( Figure 1B ). These adhesive interactions between cells of the same and different types that occur by binding extracellular Galectin-3 allow Galectin-3 to promote homotypic and heterotypic aggregation, in particular in metastatic processes (15) (16) (17) .
Galectin-3 is expressed on numerous immune cells and possesses several immunomodulating activities, such as promoting chemotaxis (18) , inducing cell-cell adhesion (for instance, dendritic cell-T cell) and cell-matrix glycoprotein adhesion (19) , regulating cell proliferation and survival (8, 20) , and favouring superoxide production and phagocytosis by macrophages. It has been suggested that Galectin-3 also influences the strength of antigen activation in dendritic cells (21, 22) and controls acquired immunity, including both T-helper cell 1 (Th1) (23, 24) and T-helper cell 2 (Th2) responses (21, 25) depending on the context of the host immune response. Along with its role in inflammation and immune responses in noninfectious conditions, Galectin-3 can detect certain microorganisms by binding specific carbohydrate structures of glycoproteins and glycolipids from many pathogens (26) . Recently, it has been reported that Galectin-3 acts as a novel alarmin by augmenting the inflammatory response in sepsis development during bacterial pneumonia following Francisella novicida infection (27) . The alarmin properties of Galectin-3 include stimulation of an oxidative burst in neutrophils and inflammatory cytokine production in macrophages (27) .
Taken together, these studies show that Galectin-3 is a versatile molecule that binds a plethora of intra-and extracellular ligands, thus activating different physiological processes inside and outside the cells. Further, Galectin-3 exerts diverse and sometimes opposing functions under various pathological conditions, depending on the specific tissue and cellular milieu. We will discuss how this molecule contributes to the immunopathology of different diseases, with a specific focus on autoimmunity, inflammation and tumour progression.
GALECTIN3 IN INFLAMMATION AND AUTOIMMUNITY
Inflammation is generally protective and serves to maintain tissue homeostasis and repair. However, unbalanced inflammation becomes deleterious to the host and can lead to a variety of pathological conditions. For example, metabolic inflammation, referred to as metaflammation, is a chronic inflammation generated from expanding adipose tissue and is induced by metabolic danger signals during obesity. Metaflammation precedes the development of metabolic abnormalities such as insulin resistance, type 2 diabetes and nonalcoholic fatty liver disease. Despite the fact that Galectin-3 exhibits deleterious effects under inflammatory conditions, various studies have demonstrated its protective role in the pathogenesis of obesity-induced inflammation triggered by accumulation of different metabolic stressors, such as advanced glycation end products (AGEs) (28) . Namely, AGEs and the receptor for AGEs (RAGE) have been linked to enhanced apoptosis and dysfunction of pancreatic β cells and also to the pathogenesis of diabetic complications (29) . Galectin-3 has been identified as an AGE receptor (30) that binds AGEs with high affinity, thus acting as a scavenger receptor for these glucose adducts that are elevated in animals on a lipid-rich diet (29) . Galectin-3 protects β cells in rats from the cytotoxic effect of IL-1β (31) . The expression levels of Galectin-3 in adipocytes and macrophages of adipose tissue and in serum are elevated during obesity in both humans and experimental animals (29) .
To examine the role of Galectin-3 in obesity and type 2 diabetes, we used the model of high fat diet (HFD)-induced obesity in Galectin-3-deficient mice (32) . We showed that lack of Galectin-3 accelerates HFD-induced obesity and type 2 diabetes by increasing visceral adiposity, hyperglycaemia and insulin resistance and by upregulation of inflammatory pathways at both local (metabolic tissue) and systemic levels. Visceral adipose tissue of obese Galectin-3-deficient mice was infiltrated with type 1 CD3 
CD11b
+ CD11c + bone marrow-derived cells. In addition, regulatory T cells and, in particular, alternatively activated M2 macrophages were markedly reduced. These findings are complementary to a previous study demonstrating that Galectin-3 promotes M2-polarized macrophages (33) . In addition to visceral adipose tissue, we found that a lack of Galectin-3 is also associated with inflammation in pancreatic islets, which is reflected by the presence of severe insulitis (32) . This finding supports the concept that Galectin-3 has protective functions in metaflammation during obesity (29) .
Principal mechanisms of obesity-induced inflammation include nuclear factor-κB (NF-κB)-dependent production of proinflammatory cytokines and increased activation of the NLRP3 (NOD-like receptor family, pyrin domain containing 3) inflammasome, leading to caspase-1-mediated cleavage and release of active proinflammatory IL-1β (34) . In our study, increased expression of the NLRP3 inflammasome and IL-1β in macrophages was present in visceral adipose tissue and pancreatic islets of obese Galectin-3-deficient mice in comparison with wild type mice fed with an HFD (32) . A key point of our work is that pancreatic islets of obese Galectin-3-deficient mice had increased deposition of AGE and RAGE expression, described profibrotic IL-33/ST2/IL-13 pathway in macrophages is Galectin-3-dependent (41) .
The notion that Galectin-3 has a proinflammatory role in T-cell-mediated disease has been demonstrated in animal experimental models, such as Concanavalin A (Con A)-induced fulminant hepatitis (42) . Con A is a potent, hepatotropic T cell mitogen, and it induces acute hepatitis in a model of T lymphocyte-mediated liver damage in mice (43) . Our results demonstrate that ablation of Galectin-3 markedly attenuated liver injury by reducing the number of effector cells, such as T lymphocytes, natural killer (NK) and natural killer T (NKT) cells, and increasing the number of M2-polarized macrophages. Thus, our data support the assertion that Galectin-3 promotes inflammation in the liver following Con A injection. Further, apoptosis of liver-infiltrating cells contributes to the lower number of mononuclear cells in the livers of Galectin-3-deficient mice, supporting the concept that Galectin-3 has an antiapoptotic role, particularly if it is localized within cells (42) . Similar to the effects of deleting the Galectin-3 gene, pretreatment of wild type mice with a selective Galectin-3 inhibitor (TD139) also significantly reduced Con A-induced liver injury by suppressing infiltration of IFN-γ-, IL-17-and IL-4-producing CD4 + T lymphocytes and IFN-γ-producing CD8 + T lymphocytes, and increasing the number of IL-10-producing CD4 + T lymphocytes, as well as alternatively activated macrophages (42) . Altogether, our findings indicated that reduced inflammation in the liver of Con A-treated Galectin-3-deficient mice and TD139-pretreated wild type mice could be the result of attenuation of macrophage and T cell activity.
Primary biliary cirrhosis (PBC) is considered a progressive autoimmune liver disease with immune-mediated destruction of intrahepatic biliary epithelial cells and frequent appearances of autoantibodies against the major mitochondrial autoantigen, PDC-E2 (pyruvate dehydrogenase complex component E2) (44, 45) . It appears that biliary epithelial cells (BECs) are the major targets of injury and thus they are active participants in the initiation and perpetuation of autoimmunity in the pathogenesis of PBC. It is assumed that a unique apoptotic feature of biliary epithelial cells may contribute to epitope presentation to the immune system, causing unique tissue damage (46, 47) . In this scenario, both acquired and innate immunity have been proposed as contributors in autoimmune-mediated destruction (48) .
Our laboratory has decided to examine the role of Galectin-3 in PBC pathogenesis by using a murine model of autoimmune cholangitis following immunization of Galectin-3-deficient mice with 2-octynoic acid (2OA) coupled to BSA (2OA-BSA). In contrast to the results from our previous studies, which indicated that deletion of the Galectin-3 gene reduces several T cell-mediated autoimmune diseases, such as diabetes (49) and experimental autoimmune encephalomyelitis (50), we demonstrate here that another autoimmune disease, PBC, is aggravated by Galectin-3 deficiency (data have been accepted for pubsuggesting that deletion of the Galectin-3 gene impairs their removal, leading to accelerated inflammation and subsequent damage of pancreatic β-cells. Additionally, we noticed that this increased deposition of AGE and RAGE was accompanied by higher expression levels of phosphorylated NF-κB p65 and mature caspase-1 in pancreatic tissue and visceral adipose tissue (32) . It appears that the NF-κB-mediated proinflammatory pathway operates in the enhanced metaflammation observed in Galectin-3-deficient mice.
Recently, it has been suggested that type 2 diabetes is an autoinflammatory disease with a central role for NLRP3-ASC (apoptosis-associated speck-like protein containing a caspase recruitment domain) inflammasome-mediated IL-1β production (35) . In this regard, we noticed a trend towards increased expression of the NLRP3 inflammasome and ASC adaptor proteins in pancreatic and visceral adipose tissue, respectively. Additionally, peritoneal macrophages from Galectin-3-deficient mice released higher amounts of IL-1β and had increased NLRP3 inflammasome expression and caspase-1 activity in response to stimulation with lipopolysaccharide and/ or saturated fatty acid palmitate compared with peritoneal macrophages from wild type mice in vitro. We also noticed that silencing of the NLRP3 inflammasome attenuated IL-1β production by macrophages from Galectin-3-deficient mice, suggesting that the release of IL-1β was mediated by NLRP3 inflammasome activation. Finally, we demonstrated that obese Galectin-3-deficient mice had increased systemic inflammation, as shown by elevated serum levels of proinflammatory IL-6 and IL-1β, followed by significantly decreased serum levels of immunomodulatory IL-13 and IL-10. Altogether, the results obtained from our study suggest an important protective role of Galectin-3 in obesity-induced inflammation and type 2 diabetes (32).
Nonalcoholic fatty liver disease (NAFLD) is a common chronic metabolic complication of obesity and type 2 diabetes (36). Liver steatosis is a benign condition that progresses to nonalcoholic steatohepatitis (NASH), which is characterized by chronic liver inflammation and fibrosis (37) . The liver is the main catabolic site for AGEs and ALEs (advanced lipoxidation end-products) (38) . Recently, it has been reported that Galectin-3 is involved in the regulation of fatty acid and glucose metabolism in the liver (39) . RAGE, found predominantly in hepatocytes, and Galectin-3, which is highly expressed in sinusoidal liver endothelial and Kupffer cells, are the principal scavenger receptors for AGEs/ALEs and are involved in their removal without initiation of inflammation (40) . To clarify the role of Galectin-3 in the pathogenesis of obesityrelated NASH, Galectin-3-deficient mice were placed on the obesogenic HFD (41) . The data obtained show that Galectin-3 attenuates steatosis but promotes liver injury, inflammation and fibrosis, thus regulating disease progression in the obesogenic mouse model of NASH. In addition, we show here for the first time that the newly lication). This autoimmune disease is characterized by increased periportal infiltration, bile duct damage, granulomas and fibrosis. It is well established that intracellular Galectin-3 is a critical negative regulator of apoptosis. Thus, the cause of these differences appears to be the fact that in PBC, the ablation of Galectin-3 leads to increased availability of autoantigen(s). In actuality, lack of Galectin-3 may affect mitochondrial membrane integrity and resistance to apoptosis in BECs and, consequently, cause the release of putative antigen(s) that induce a stronger activation of DCs, a higher influx of inflammatory lymphocytes, and enhanced bile duct damage and liver fibrosis. In addition, we did not detect Galectin-3 expression in BECs from healthy wild type mice. However, the expression of Galectin-3 was significantly increased in BECs from 2OA-BSA-immunized mice. Finally, we assume that increased expression of Galectin-3 in BECs in the murine model of autoimmune cholangitis is probably a compensatory mechanism that is used to protect the BECs from apoptosis induced by different stimuli.
PROTUMOURIGENIC ROLE OF GALECTIN3
Galectin-3 expression is altered or abnormally localized in cells of various human solid tumours and blood malignancies, suggesting that this multifunctional molecule may modulate tumour progression and influence disease outcome (1, 51) . Some immunohistochemistry studies have indicated that overexpression of Galectin-3 may be a prognostic factor for poor survival of patients with gastric cancer, hepatocellular carcinoma, thyroid cancer and leukaemia (52) (53) (54) (55) (56) . It seems that the translocation of Galectin-3 from the cytoplasm to the nucleus of melanoma cells results in a more aggressive phenotype (57) . Interestingly, tumour hypoxia upregulates the expression of Galectin-3 and also leads to changes in its subcellular localization (58) . Under hypoxic conditions, the expression of Galectin-3 shifts from a nuclear location to cytoplasmic and membranous locations, suggesting that this shift favours resistance to apoptosis and malignancy of mammary tumour cells (58) . Circulating Galectin-3 is also increased in the bloodstream of cancer patients. Thus, markedly higher serum concentrations of Galectin-3 were found among patients with many types of cancer (59-61), compared with those of healthy individuals. Additionally, patients with advanced melanoma have higher concentrations of circulating Galectin-3 than those with localized tumours. It appears that the source of increased Galectin-3 concentrations in the serum of patients with cancer may be the tumour cells, as well as the peritumoural inflammatory and stromal cells (16, 59) .
Despite its involvement in physiological processes, Galectin-3 is also a key player in many steps of tumour development and metastasis. It has been demonstrated that Galectin-3 favours a broad range of cancer cell activities, such as malignant cell transformation and tumour growth (62) (63) (64) , cell adhesion, migration and invasion (65-69), anoikis resistance (70), apoptosis inhibition (71), (72) and angiogenesis (73) .
Galectin-3 can promote malignant transformation due to simultaneous stimulation of cell growth and prevention of apoptosis. For example, nuclear Galectin-3 can interact with β-catenin to enhance the expression of cyclin D and c-Myc (74) and thus promote cell cycle progression (14) . This galectin can upregulate β-catenin expression in the nucleus of human colon cancer cells and augment Wnt/β-catenin signalling by regulating glycogen synthase kinase-3β (GSK-3β) phosphorylation and activity via the PI3K/ Akt pathway (75) . Additionally, cytoplasmic Galectin-3 may cause constitutive activation of Ras-dependent PI3K and Raf-1 activation by its interaction with activated K-Ras (63) . Altogether, these results suggest that Galectin-3 is a pivotal player in the regulation of cancer-related gene expression and the activation of many signalling pathways. One of the main hallmarks of cancer is the evasion of apoptosis that contributes to cancer cells' survival. An additional function of Galectin-3 that is relevant to tumour progression is inhibition of apoptosis. Following apoptotic stimuli, Galectin-3 translocates from either the cytosol or the nucleus to the mitochondria (4), where it interacts with Bcl-2 and blocks the alteration of mitochondrial membrane potential and cytochrome-c release (71) . It has also been reported that Galectin-3 heterodimerizes with Bax, mediated by the carbohydrate recognition domain of Galectin-3, which leads to attenuation of apoptosis in human thyroid carcinoma cells (76) . Further, this galectin is an important antiapoptotic effector molecule that confers resistance to conventional cancer chemotherapy. Thus, when leukaemia cells were treated with cisplatin, Galectin-3 expression was upregulated and caused resistance to apoptosis in surviving cells (77) . In contrast, silencing of Galectin-3 in gastric cancer cells augments apoptosis induction by chemotherapy by decreasing the expression of cell survival molecules (e.g., survivin and cyclin D1) (78) . Additionally, the silencing of Galectin-3 with RNA interference also sensitizes multidrug-resistant cells to epirubicin by activation of the mitochondrial apoptosis pathway through modulation of the β-catenin/GSK-3β pathway in human colon cancer cells (79) .
The migratory and invasive potential of tumour cells is associated with tumour progression. The invasion and metastasis processes involve changes in several proteins engaged in cell-cell and cell-matrix adhesion (2), and cell surface expression of Galectin-3 seems to contribute to these processes, thus promoting the metastatic spread of cancer cells from primary to secondary tumour sites (51, 80) . Adhesive interaction with components of the extracellular matrix (ECM) is important for migration of malignant cells (81) . It is well established that Galectin-3 interacts with glycoproteins of the ECM, such as fibronectin, collagen IV, elastin and laminin (19, 82) . It appears that increased levels of Galectin-3 in the bloodstream of cancer patients can be critical in malignant cell metastasis (16) . One of the Galectin-3 binding partners is oncofoetal Thomsen-Friedenreich antigen, which is on the transmembrane mucin protein MUC1 expressed by many metastatic cells (83) . This interaction results in increased tumour cell homotypic aggregation to form microtumour emboli that prolong metastatic cell survival in the circulation by prevention of anoikis and enhanced heterotypic adhesion of the metastatic cells to the vascular endothelium (83) (84) (85) .
A critical step in successful establishment of organspecific metastasis is the adhesion interactions of tumour cells with the host microenvironment, especially interactions with components of the ECM and vascular endothelium in target organs. It appears that the degree of organ-specific metastasis may be associated with Galectin-3 expression in the lungs. In this regard, we reported that Galectin-3 ablation in the host markedly decreases lung melanoma metastasis. In an experimental model of B16-F1 murine melanoma, we demonstrated that Galectin-3-deficient mice were more resistant to metastatic melanoma, as evidenced by markedly reduced number and size of lung metastatic colonies compared with wild type mice. In addition, by in vitro assay we noticed lower numbers of attached malignant cells in lung tissue sections of Galectin-3-deficient mice, suggesting that hostderived Galectin-3 plays a pivotal role in tumour cell adhesion to the metastatic target (86) . Recently, it has been shown that Galectin-3, which is expressed in lungs (especially on the vascular endothelium), cooperates with poly-N-acetyl-lactosamine on N-glycans on B16-F1 murine melanoma cells, as a ligand for Galectin-3 (87) . This interaction between Galectin-3 and its glycoprotein ligand not only facilitates initial adhesion of tumour cells to the vascular endothelium but also participates in subsequent metastatic processes such as extravasation, degradation of the matrix and organ colonization (88) . Finally, metastatic cells continue to proliferate in the target organ. Tumour angiogenesis is involved in the metastatic cascade both at the primary site and at downstream sites of metastasis. In addition to its role in dissemination of tumour cells, angiogenesis is also required for expansion of the metastatic colony in the target tissue. It appears that Galectin-3 has proangiogenic activity via interactions with several endothelial cell surface receptors. For example, Galectin-3 interacts with αvβ3 integrin on endothelial cells and induces promotion of VEGF-and bFGF-mediated endothelial migration and, consequently, vessel branch formation (89) .
Immune evasion and suppression are associated with tumour progression through inhibition of effector immune cells or via expansion of immunosuppressive cells (90, 91) . Galectin-3 is an important modulator of immune responses through the regulation of homeostasis and immune cell function. For example, Galectin-3 reduces the affinity of the T-cell receptor (TCR) for major histocompatibility complex (MHC) Class I and peptide ligand by segregating the TCR from its CD8 coreceptor (92) , disrupts the immunological synapse by internalizing the TCR (93) , and induces apoptosis of T cells (94) .
It is well established that NK cells and CD8
+ cytotoxic T cells are crucial players in the control of melanoma growth and metastasis. Recently, Kouo et al. (95) suggested that Galectin-3 modulates antitumour immune responses by suppressing effector CD8 + T cells exclusively in the tumour microenvironment via lymphocyte activation gene 3 (LAG-3), an inhibitory receptor that is associated with regulation of terminal T-cell activation/exhaustion. Our data support a link between Galectin-3 and the cytotoxic capacity of NK cells, but not that of CD8 + T cells. In fact, we demonstrated that lack of Galectin-3 is associated with enhanced tumouricidal activity of NK cells directed against B16-F1 melanoma cells (86 (86) . It is believed that Galectin-3 interferes with binding to regulatory molecules on the cancer cell that serve as ligands for receptors of NK cells (96) . Additionally, the results from Wang et al. (97) suggested that expression of membrane KLRG1 receptors on NK cells impairs their activation and IFN-γ production, but increases apoptosis of these cells in chronic hepatitis C virus infection.
Some evidence suggested that Galectin-3 is associated with a decrease in regulatory T (Treg) cell frequency and thus influences the course of experimental autoimmune encephalomyelitis and Leishmania major infection (98, 99) . These results raise the question of whether Galectin-3 deficiency also impaired the number of Treg cells in an experimental model of B16-F1 murine melanoma. We noticed that injection of melanoma cells resulted in marked increases in the percentage and total number of regulatory CD4 +
Foxp3
+ T cells in wild type mice, but not in Galectin-3-deficient mice (86) . Thus, our findings suggest that hostderived Galectin-3 could lead to an increase in the number and percentage of Treg cells, which promotes the formation of an immunosuppressive tumour network and can be one of the main facilitative mechanisms important for tumour metastasis. A high number of Treg cells has been directly correlated to cancer progression (100). In our experimental model of B16-F1 murine melanoma, it appears that the most important role of Treg cells is suppression of NK cell function. A previous study demonstrated that a high number of Treg cells was inversely correlated to the frequency and function of NK cells (100) . For example, cocultivation of human allogeneic Treg cells with resting NK cells led to markedly reduced NK cell natural cytotoxicity, cytokine production and expression of NKG2D activating receptors in vitro (101) .
While IL-17 exhibited both protumour and antitumour roles (102), IFN-γ exerted potent antitumour immunity against melanoma and various other cancers (103) . It has been reported that IFN-γ has direct antiproliferative and proapoptotic effects on tumour cells in animal models (104, 105) and that these effects prevent B16 experimental metastasis by directly inhibiting cell growth (106) . We observed higher serum levels of IFN-γ and IL-17 in tumour-bearing hosts in Galectin-3 deficiency, which was not accompanied by differences in the number of CD4 + and CD8 + T cells in the spleen. This does not exclude the possibility that the number of tumour-specific Th1 cells and cytotoxic CD8 + T cells is different (86) . Reported data suggest that Galectin-3 suppresses IFN-γ production by antigen-specific CD8 + T cells in vitro (95) . Further, dendritic cells lacking the Galectin-3 gene have been shown to increase both T-cell numbers and cytokine production in helminthic infections and promote an effective Th17 immune response (107, 108) . Altogether, it appears that Galectin-3 is involved in the tuning of acquired immunity against tumours by determining the cytokine milieu in the tumour microenvironment.
In summary, our data determined several findings supporting Galectin-3 as a potential facilitator of melanoma lung metastasis. First, host-derived Galectin-3 is a critical player in tumour cell adhesion to the metastatic target and thus contributes to the initial adhesion and survival of circulating metastatic cells. Second, Galectin-3 shapes the immune response against B16-F1 melanoma cells by suppressing effector NK cells and enhancing expansion of CD4 + Foxp3 + T cells. Thus, our findings clearly confirm the results obtained in other studies suggesting that Galectin-3 has a wide range of pivotal protumourigenic functions that are associated with tumour growth and metastasis, implying that it would be an ideal therapeutic target to prevent tumour progression.
EXPERT OPINION
The cell-and tissue-specific profiles of Galectin-3 expression differ under physiological and pathological conditions (14, 109, 110) ; they can undergo a variety of changes under the stress conditions encountered in tumour microenvironments, inflammation or fibrosis. Divergent specificities and affinities of Galectin-3 for various glycoproteins appear to contribute to the multiplicity of its activities.
Galectin-3 is a highly versatile protein and a potent modulator of pivotal cellular processes. The role of Galectin-3 in various pathological conditions is complex, with diverse and sometimes opposing functions. We report herein that Galectin-3 exhibits deleterious roles in the promotion of tumour progression and liver inflammation after Con A injection and the aggravation of T cell-mediated autoimmune diseases such as type 1 diabetes and experimental autoimmune encephalomyelitis. However, it appears that Galectin-3 has a protective function in conditions such as type 2 diabetes and primary biliary cirrhosis. In addition, the paradoxical role of Galectin-3 in nonalcoholic steatohepatitis during obesity is reflected in the fact that it contributes to inflammation and fibrosis in the liver, but reduces steatosis (as illustrated in Figure 2 ). The functional dichotomy in various pathological conditions suggests that the effects of Galectin-3 depend on cellular and tissue localization, or the availability, glycosylation status or expression level of its ligands.
The key question is: How does Galectin-3 achieve its target specificity to become a meaningful effective molecule? The identification and characterization of the nature and structural diversity of Galectin-3 ligand(s) (e.g., glycoconjugate or protein) responsible for target selectivity (111) will be the basis for not only developing rational antiinflammatory and antitumoural approaches but also for taking advantage of the protective functions of Galectin-3 in metabolic abnormalities or primary biliary cirrhosis. Specifically, the major aim for therapeutic manipulation is singling out the pathological aspect in target tissue while avoiding harm at the physiologic site. Ideally, Galectin-3 therapy should be strictly spatially confined.
